• 1
    Felber SR, Sperl W, Chemelli A, Murr C, Wendel U. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993; 33: 396401.
  • 2
    Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 2002; 109: 9991008.
  • 3
    Riviello JJ Jr., Rezvani I, DiGeorge AM, Foley CM. Cerebral edema causing death in children with maple syrup urine disease. J Pediatr 1991; 119: 4245.
  • 4
    Strauss KA, Morton DH. Branched-chain ketoacid dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol 2003; 5: 329341.
  • 5
    Levin ML, Scheimann A, Lewis RA, Beaudet AL. Cerebral edema in maple syrup urine disease. J Pediatr 1993; 122: 167168.
  • 6
    Lungarotti MS, Calabro A, Signorini E, Garibaldi LR. Cerebral edema in maple syrup urine disease. Am J Dis Child 1982; 136: 648.
  • 7
    Kaplan P, Mazur AM, Smith R, Olthoff K, Maller E, Palmieri M. Transplantation for maple syrup urine disease (MSUD) and methylmalonic acidopathy (MMA). J Inher Metab Dis 1997; 20: 37.
  • 8
    Young VR. Nutrient interactions with reference to amino acid and protein metabolism in non-ruminants; particular emphasis on protein-energy relations in man. Z Ernahrungswiss 1991; 30: 239267.
  • 9
    Young VR. 1987 McCollum award lecture. Kinetics of human amino acid metabolism: nutritional implications and some lessons. Am J Clin Nutr 1987; 46: 709725.
  • 10
    Levy HL. Hartnup disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Volume 3. 8th Edn. New York : McGraw-Hill, 2001; 49574970.
  • 11
    Schadewaldt P, Hammen HW, Ott AC, Wendel U. Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease. J Inherit Metab Dis 1999; 22: 706722.
  • 12
    Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 1999; 96: 1207912084.
  • 13
    Killian DM, Chikhale PJ. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. Neurosci Lett 2001; 306: 14.
  • 14
    Matsuo H, Tsukada S, Nakata T et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 2000; 11: 35073511.
  • 15
    Umeki N, Fukasawa Y, Ohtsuki S et al. mRNA expression and amino acid transport characteristics of cultured human brain microvascular endothelial cells (hBME). Drug Metab Pharmacokinet 2002; 17: 367373.
  • 16
    Brosnan JT. Interorgan amino acid transport and its regulation. J Nutr 2003; 133: 2068S2072S.
  • 17
    Schadewaldt P, Bodner-Leidecker A, Hammen HW, Wendel U. Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease. Clin Chem 1999; 45: 17341740.
  • 18
    Mazariegos GV, Sindhi R, Soltys K et al. Rabbit anti-thymocyte globulin (rATG) induction therapy in pediatric steroid-free liver transplantation: one–two year follow-up. Am J Transplant 2005; 5: 392393.
  • 19
    Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr 1998; 68: 7281.
  • 20
    Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 18971905.
  • 21
    Dorner G, Bewer G, Lubs H. Changes of the plasma tryptophan to neutral amino acids ratio in formula-fed infants: possible effects on brain development. Exp Clin Endocrinol 1983; 82: 368371.
  • 22
    Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr 2000; 71: 1669S1675S.
  • 23
    Hutchison SN, Zarghami NS, Cusick PK, Longenecker JB, Haskell BE. The effect of valine deficiency on neutral amino acid patterns in plasma and brain of the rat. J Nutr 1983; 113: 21642170.
  • 24
    Kamei A, Takashima S, Chan F, Becker LE. Abnormal dendritic development in maple syrup urine disease. Pediatr Neurol 1992; 8: 145147.
  • 25
    Roach MK, Corbin J, Pennington W. Effect of undernutrition on amino acid compartimentation in the developing rat brain. J Neurochem 1974; 22: 521528.
  • 26
    Yudkoff M, Daikhin Y, Nissim I et al. Brain amino acid requirements and toxicity: the example of leucine. J Nutr 2005; 135: 1531S1538S.
  • 27
    Fernstrom JD. Branched-chain amino acids and brain function. J Nutr 2005; 135: 1539S1546S.
  • 28
    Smith QR, Takasato Y. Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann N Y Acad Sci 1986; 481: 186201.
  • 29
    Araujo P, Wassermann GF, Tallini K et al. Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats. Neurochem Int 2001; 38: 529537.
  • 30
    Zielke HR, Zielke CL, Baab PJ, Collins RM. Large neutral amino acids auto exchange when infused by microdialysis into the rat brain: implication for maple syrup urine disease and phenylketonuria. Neurochem Int 2002; 40: 347354.
  • 31
    Yudkoff M, Daikhin Y, Grunstein L et al. Astrocyte leucine metabolism: significance of branched-chain amino acid transamination. J Neurochem 1996; 66: 378385.
  • 32
    Yudkoff M, Daikhin Y, Nissim I, Pleasure D, Stern J, Nissim I. Inhibition of astrocyte glutamine production by alpha-ketoisocaproic acid. J Neurochem 1994; 63: 15081515.
  • 33
    Rela M, Muiesan P, Heaton ND et al. Orthotopic liver transplantation for hepatic-based metabolic disorders. Transpl Int 1995; 8: 4144.
  • 34
    Shneider BL. Pediatric liver transplantation in metabolic disease: clinical decision making. Pediatr Transplant 2002; 6: 2529.
  • 35
    Castilla Cabezas JA, Lopez-Cillero P, Jimenez J et al. Role of orthotopic liver transplant in the treatment of homozygous familial hypercholesterolemia. Rev Esp Enferm Dig 2000; 92: 601608.
  • 36
    McDiarmid SV, Millis MJ, Olthoff KM, So SK. Indications for pediatric liver transplantation. Pediatr Transplant 1998; 2: 106116.
  • 37
    Mazariegos GV. Withdrawal of immunosuppression in liver transplantation: lessons learned from PTLD. Pediatr Transplant 2004; 8: 210213.
  • 38
    Himelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric palliative care. N Engl J Med 2004; 350: 17521762.